Arcus Biosciences, Inc. (RCUS) Q4 2019 Earnings Results

Arcus Biosciences Misses on EPS, Stock Up 6.78%

The earnings report indicates that Arcus Biosciences is still in a development phase, as reflected by the negative EPS. However, the stock rose by 6.78%, likely due to investor optimism about ongoing clinical trials and management's positive messaging. The lack of revenue data and guidance suggests uncertainty, but the market reacted favorably to the overall progress reported.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.38	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a positive outlook on their research initiatives. They emphasized the importance of their clinical trials moving forward.

Management highlighted ongoing progress in clinical trials.

They expressed confidence in their pipeline despite not providing specific guidance.

Arcus Biosciences Misses on EPS, Stock Up 6.78%

Key numbers

Management commentary

Arcus Biosciences, Inc.

More earnings this week

Arcus Biosciences Misses on EPS, Stock Up 6.78%

Key numbers

Management commentary